id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-307334-6rn69sne	Sullivan, Ryan J	COVID-19 and immune checkpoint inhibitors: initial considerations	2020-05-19		.txt	text/plain	1751	117	41	One important clinical question is how to manage patients who need anticancer therapy, including immune checkpoint inhibitors (ICIs) during these conditions. One important clinical question is how to manage patients who need anticancer therapy, including immune checkpoint inhibitors (ICIs) during these conditions. While more robust data are needed to guide clinicians on management of patients with cancer who may be affected by COVID-19, we hope this commentary provides useful insights for the clinical community. While more robust data are needed to guide clinicians on management of patients with cancer who may be affected by COVID-19, we hope this commentary provides useful insights for the clinical community. 2 4 5 Less clear are the effects of newer antineoplastic therapies, especially immune checkpoint inhibitors (ICIs), on COVID-19 severity. Dry cough and dyspnea without fever could point toward ICI-pneumonitis, respiratory viral infection (including COVID-19), or other non-infectious etiologies common in patients with cancer. Finally, should asymptomatic patients initiating ICI be screened for active COVID-19 infection prior to starting therapy?	./cache/cord-307334-6rn69sne.txt	./txt/cord-307334-6rn69sne.txt